GlassScriptPhysician profile
Brandon K Bean
NPI 1356427199
$2,430.28
in general payments reported to CMS, 2019-2025
16 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $30.20 · 2021: $232 · 2022: $385 · 2023: $558 · 2024: $639 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.49 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $540.33 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $496.94 | 2021-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $311.13 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $242.89 | 2020-2025 | Jynarque |
| Amgen INC. | $172.56 | 2022-2023 | Parsabiv |
| Horizon Therapeutics Plc | $156.56 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $107.92 | 2019 | |
| Akebia Therapeutics INC | $96.78 | 2020-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $82.39 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $59.10 | 2023-2024 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.84 | 2024-2025 | Jardiance |
| Medtronic, INC. | $31.90 | 2023 | Ellipsys Vascular Access System |
| Daiichi Sankyo INC. | $30.38 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $21.07 | 2025 | Terlivaz |
| Vifor Pharma, INC. | $14.80 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.69 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.